Saturday Nov 30
Trader's Buzzers- Endo Health Solutions Inc (NASDAQ:ENDP), Estee...
CaddyStocks.com is keen to discover penny stocks with the potential to make short and long-term gains.
Tue Nov 26, 2013
RLPC: Endo markets $4.3B refinancing package
Malvern, Pennsylvania-based healthcare company Endo Health Solutions is marketing a $4.3 billion bond and loan refinancing package in conjunction with its $1.6 billion acquisition of Paladin Labs Inc, sources told Thomson Reuters LPC.
'Greed Is Good': Hologic Attracts The Value Crowd
Hologic gapped up last Thursday morning after activist investor Carl Icahn reported a 12.63% stake in the $6 billion diagnostic company.
Wed Nov 20, 2013
Endo Health Solutions Inc. Announces Consent Solicitation To Amend Senior Notes
Subject to the terms and conditions set forth in the Statement, Endo will pay eligible holders who validly deliver and do not revoke their consents on or prior to , as may be extended by Endo with respect to one or more series of the Notes in accordance with the Statement , a cash payment equal to aggregate principal amount of each series of Notes ... (more)
Tue Nov 19, 2013
Duly Noted: City expands drug marketing investigation
Chris Caso, senior research analyst at Susquehanna Financial Group, offers his expectations of the iPhone 6 gathered together from conversations with members of Apple's supply chain.
Mon Nov 18, 2013
New Magic Formula Stocks From Joel Greenblatt: URS, Nabors Industries, Pilgrims Pride, NeuStar, ...
Renowned value investor, the inventor of magic formula investing, Joel Greenblatt just reported his third quarter portfolio.
Thu Nov 14, 2013
Blue Ridge Capital Buys Charter Communications, American Homes 4 Rent, Tesla Motors, Sells ...
Hedge fund Blue Ridge Capital just reported its third quarter portfolio. The fund is run by John Griffin , who was the right hand man of the legendary hedge fund giant Julian Robertson .
Wed Nov 13, 2013
Paladin Announces Extension of the Impavido PDUFA Date by Three Months
Paladin Labs Inc. , a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has notified Paladin that it is extending the Prescription Drug User Fee Act goal date for its new drug application for ImpavidoA for the treatment of cutaneous, mucosal, and visceral leishmaniasis from December 19, 2013 to March 19, ... (more)
Tue Nov 12, 2013
Endo Tax Edge for Deals Mimics Valeant Playbook: Real M&A
Endo Health Solutions Inc. 's recent acquisition designed to lower its tax rate may be following Valeant Pharmaceuticals International Inc.'s blueprint for a lucrative takeover spree.
Citigroup Reiterates on Endo Health Solutions on Potential of Paladin Acquisition
In a report published Tuesday, Citigroup analyst Liav Abraham reiterated a Buy rating on Endo Health Solutions , and raised the price target from $43.00 to $70.00.
Trend Analysis Report: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN),...
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Mon Nov 11, 2013
Paladin Announces Extension of the Impavido(R) PDUFA Date by Three Months
During the course of recent discussions with the FDA, Paladin submitted revisions regarding chemistry, manufacturing and control details and other aspects related to the proposed label.
Stocks Highlights: US Airways Group Inc
Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages.
Sun Nov 10, 2013
Endo Health Solutions PT Raised to $62.00 at Susquehanna
The firm currently has a "neutral" rating on the stock. Susquehanna's price target would indicate a potential upside of 2.48% from the company's current price.
Endo Health Solutions Price Target Raised to $63.00 at Ubs Ag
The firm currently has a "buy" rating on the stock. UBS AG's price target indicates a potential upside of 4.13% from the company's current price.
Fri Nov 08, 2013
Endocan Corporation CFO and Sr. VP of Business Development, Robert Kane, Interviewed on 'StockRadio.com' Regarding Company Developments and Forward Looking Strategy for 2014 - CW15 - OMAHA Endocan Corporation CFO and Sr. VP of Business Development, Robert Kane, Interviewed on 'StockRadio.com' Regarding Company Developments and Forward Looking ... (more)